Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at eradicating tumor cells but with a focus on safety and reducing toxic side effects. In this way, we can both treat the disease and improve patient quality of life and outcomes at the same time. We have used our core expertise of protein engineering to target the most common pediatric cancer as well as infamously difficult to treat cancers like acute myeloid leukemia and the solid tumors pancreatic, liver, and ovarian cancers. Utilizing drug mechanisms of action and patient genomic and epigenetic markers will guide our clinical strategy as we move forward to make sure that only patients likely to benefit from our biologics will be receiving them.